

**ASX Announcement**5 October 2022

---

**Company Appointment – Chief Commercial Officer**

Antisense Therapeutics Limited (“ANP” or “the Company”) is pleased to announce the appointment of Dr Anthony Filippis as the Company’s Chief Commercial Officer (CCO).

Anthony is an internationally experienced senior leader with deep understanding and knowledge of the biotechnology, pharmaceutical, healthcare and investment industries. He is currently the CEO & Managing Director of Neurosciences Victoria Limited (NSV), a role he has held since 2017. Anthony is an accomplished executive with over 25 years’ experience in business development, corporate strategy, operations, and senior management in ASX-listed and private companies. He has a strong track record in negotiating transactions, partnering (in- and out-licensing), M&A and raising capital for drug development, medical device and diagnostics companies in various fields including neuroscience, oncology, endocrinology and rare diseases.

At Antisense Therapeutics, Anthony will have responsibility for the negotiation and execution of partnering transactions as approved by the Board. Anthony will also provide commercial advice and leadership on the Company’s development programs and commercialisation plans. Anthony will look to establish/expand on the Company’s business development and partnering activities across its various programs and to detail the features of these programs with potential partners through direct contact and attendance at relevant international conferences. Anthony will assist in the process for accessing additional development capital and will also have an important role in supporting the Company’s investor relations activities with a strategic focus on the US to increase the Company’s profile in that key market.

Anthony’s most recent career achievements include spearheading the investment of \$50m for traumatic brain injury research, \$12m for mental health clinical trials and \$40m for stroke research. In total, Anthony has been involved in successful applications for >\$130m worth of R&D funding over the last three years. Throughout his career, Anthony has closed many biotech deals, including multimillion-dollar licensing, M&A, and capital raising transactions, with companies including AstraZeneca, Schering Plough (acquired by Merck), and Meditech (acquired by Alchemia).

Anthony has been a consultant to many international companies, including Takeda Pharmaceuticals (USA), Mundipharma (UK), and Solasia K.K. (Japan) and an experienced Non-Executive Director on Boards, including NSV, Impel Neuropharma Australia Pty Ltd, Cerebral Therapeutics Pty Ltd, AnaptysBio Pty Ltd, MingSight Pharmaceuticals Pty Ltd, Qponics Ltd and Connectivity Ltd. Currently, Anthony is Chair of the Commercialisation Committee of the Australian Stroke Alliance Ltd and is a member of its Risk & WHS Committee. Anthony is also a Founder of Senz Oncology Pty Ltd.

“Anthony brings a depth of experience that will be invaluable in the execution of our product development and commercialisation plans” said Mark Diamond, Antisense Therapeutics Managing Director and Chief Executive Officer. “Anthony has developed strong commercial management skills through his CEO, Executive and Non-Executive Director, Vice President and Founder positions within the healthcare industry. Anthony’s skills and experience truly span the entire value-chain, from innovation to translation, through to commercialisation. Anthony has completed numerous deals and raised capital internationally. We are delighted to have such a seasoned biotech executive with acknowledged entrepreneurial flair join our leadership team”.

Anthony received his PhD in biochemistry from the University of Melbourne and holds an MBA, specialising in entrepreneurship and innovation and new venture creation from La Trobe University. Anthony will commence at Antisense Therapeutics in mid-November.

*This announcement has been authorised for release by the Board.*

**Antisense Therapeutics**

Mark Diamond  
Managing Director and CEO  
+61 (0)3 9827 8999  
[www.antisense.com.au](http://www.antisense.com.au)

**Investment Enquiries**

Gennadi Koutchin  
XEC Partners  
[gkoutchin@xecpartners.com.au](mailto:gkoutchin@xecpartners.com.au)  
1300 932 037

**US/European IR & Media**

Laine Yonker/Joe Green  
Edison Investor Relations  
[lyonker@edisongroup.com](mailto:lyonker@edisongroup.com)  
+1 646-653-7035

**About Antisense Therapeutics Limited** [ASX:ANP | US OTC:ATHJY | FSE:AWY], is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHR production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.